The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Kristian Pietras

Kristian Pietras

Research team manager

Kristian Pietras

Dialysis as a Novel Adjuvant Treatment for Malignant Cancers

Author

  • Sture Hobro
  • Anders Nilsson
  • Jan Sternby
  • Carl Öberg
  • Kristian Pietras
  • Håkan Axelson
  • Ana Carneiro
  • Sara Kinhult
  • Anders Christensson
  • Jonas Fors
  • Steven Maciejewski
  • Jason Knox
  • Innas Forsal
  • Linda Källquist
  • Viktoria Roos
Show all

Summary, in English

Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently increase blood ketone body levels and reduce glutamine levels, which may further reinforce the impact of the KC. Importantly, ketones also induce epigenetic changes imposed by histone deacetylates (HDAC) activity (Class I and Class IIa) known to play an important role in cancer metabolism. Thus, dialysis could be an impactful and safe adjuvant treatment, sensitizing cancer cells to traditional cancer treatments (TCTs), potentially making these significantly more efficient.

Department/s

  • Renal physiology and peritoneal dialysis
  • LUCC: Lund University Cancer Centre
  • Experimental oncology
  • Kidney cancer research group
  • Lund Melanoma Study Group
  • Internal Medicine - Epidemiology
  • EpiHealth: Epidemiology for Health

Publishing year

2022

Language

English

Publication/Series

Cancers

Volume

14

Issue

20

Document type

Journal article review

Publisher

MDPI AG

Topic

  • Cancer and Oncology

Keywords

  • cancer
  • chemotherapies
  • dialysis
  • HDAC
  • immunotherapies
  • ketone bodies
  • radiotherapies
  • redox balance

Status

Published

Research group

  • Renal physiology and peritoneal dialysis
  • Experimental oncology
  • Kidney cancer research group
  • Lund Melanoma Study Group
  • Internal Medicine - Epidemiology

ISBN/ISSN/Other

  • ISSN: 2072-6694